Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.

Date publication

mars 2026

Journal

Inflammatory bowel diseases

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Sands BE, Clemow DB, D'Haens G, Irving PM, Kobayashi T, Peyrin-Biroulet L, Samaan K, Gaur A, Arora R, Todd K, Moses R, Dignass A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41777218

Résumé

Mirikizumab, an anti-interleukin-23 monoclonal antibody targeting the p19 subunit, has shown efficacy in inducing and maintaining clinical remission in patients with moderately-to-severely active ulcerative colitis (UC). This report summarizes the final long-term outcomes from the LUCENT-3 open-label extension (OLE) through week (W)212 of continuous treatment.

Mots clés

interleukin-23 p19 antibody, long-term extension, mirikizumab, ulcerative colitis, week 212 results

Référence

Inflamm Bowel Dis. 2026 03 2;: